Skip to main content

Table 1 Demographic, baseline clinical, and medications among the two groups

From: Effect of carvedilol versus nebivolol on insulin resistance among non-diabetic, non-ischemic cardiomyopathy with heart failure

  Carvedilol group (N = 25) Nebivolol group (N = 18) P value
Age 50.5 ± 10.5 50.9 ± 9.6 0.89
Wt (kg ) 83.3 ± 12 81.4 ± 10 0.58
BMI(kg/m2) 37.0 ± 6.1 36.8 ± 4.3 0.9
Waist circum(cm ) 118.6 ± 10.5 117.3 ± 9.9 0.68
Male gender 14 (56%) 10 (55.6%) o.8
Smokers 8 (33%) 4 (22.2%) 0.48
TG (mg/dl) 132 ± 4.5 134 ± 3.5 0.12
HDL(mg/dl) 38 ± 6.2 39 ± 5.3 0.59
Uric acid(mg/dl) 8.1 ± 2.6 8.0 ± 2.3 0.89
Hb% (gm) 13.5 ± 1.2 13.0 ± 2.1 0.36
Medications    
 Loop diuretic 17 (68%) 12 (66.7%) 0.93
 Aldosterone blocker 15 (60%) 5 (27.8%) 0.036*
 RAS blocker 23 (92%) 17 (94.4%) 0.99
 Digoxin 6 (24%) 4 (22.2%) 0.99
 ASA 19 (76%) 14 (77.8%) 0.99
  1. ASA aspirin, BMI body mass index, HB hemoglobin, HDL high-density lipoprotein, RAS renin-angiotensin-system, TG triglyceride
  2. *P is significant